Learning curves of GreenLEP and HoLEP provided roughly similar peri-operative and short-term functional outcomes.

This prospective evaluation shows that day-case HoLEP may be performed by a trained surgeon with an appropriate patient selection.

In imperative indication of nephron-sparing treatment for a kidney tumor, either PN or AT can be proposed. PN offers the ability to manage larger and more complex tumors while providing a better local control and a similar renal function loss.

No abstract